New Therapies Targeting Cystogenesis in Autosomal Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease is the most common inherited kidney disease and results from mutations in the polycystin 1 gene (PKD1) or the polycystin 2 gene (PKD2). The disease is characterised by the progressive development of fluid-filled cysts derived from renal tubular epithelial...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2017-07-01
|
| Series: | European Medical Journal Nephrology |
| Subjects: | |
| Online Access: | https://www.emjreviews.com/nephrology/article/new-therapies-targeting-cystogenesis-in-autosomal-polycystic-kidney-disease/ |
| _version_ | 1818244876751339520 |
|---|---|
| author | Maurizio Salvadori Aris Tsalouchos |
| author_facet | Maurizio Salvadori Aris Tsalouchos |
| author_sort | Maurizio Salvadori |
| collection | DOAJ |
| description | Autosomal dominant polycystic kidney disease is the most common inherited kidney disease and results from mutations in the polycystin 1 gene (PKD1) or the polycystin 2 gene (PKD2). The disease is characterised by the progressive development of fluid-filled cysts derived from renal tubular epithelial cells that destroy the architecture of the renal parenchyma and lead to kidney failure. Until recently, the causes and the molecular pathways that lead to cystogenesis remained obscure. In the last decade, enormous progress has been made in understanding the pathogenesis of autosomal dominant polycystic kidney disease and developing new therapies. The purpose of this review is to provide an update on the promising therapies that are being developed and tested, based on knowledge of recent advances in molecular and cellular targets involved in cystogenesis. |
| first_indexed | 2024-12-12T14:23:59Z |
| format | Article |
| id | doaj.art-4c4dc31103ea48ea8840da53985c4bf1 |
| institution | Directory Open Access Journal |
| issn | 2053-4248 |
| language | English |
| last_indexed | 2024-12-12T14:23:59Z |
| publishDate | 2017-07-01 |
| publisher | European Medical Journal |
| record_format | Article |
| series | European Medical Journal Nephrology |
| spelling | doaj.art-4c4dc31103ea48ea8840da53985c4bf12022-12-22T00:21:44ZengEuropean Medical JournalEuropean Medical Journal Nephrology2053-42482017-07-0151102111New Therapies Targeting Cystogenesis in Autosomal Polycystic Kidney DiseaseMaurizio Salvadori0Aris Tsalouchos1Renal Unit, Careggi University Hospital, Florence, ItalyDivision of Nephrology, Careggi University Hospital, Florence, ItalyAutosomal dominant polycystic kidney disease is the most common inherited kidney disease and results from mutations in the polycystin 1 gene (PKD1) or the polycystin 2 gene (PKD2). The disease is characterised by the progressive development of fluid-filled cysts derived from renal tubular epithelial cells that destroy the architecture of the renal parenchyma and lead to kidney failure. Until recently, the causes and the molecular pathways that lead to cystogenesis remained obscure. In the last decade, enormous progress has been made in understanding the pathogenesis of autosomal dominant polycystic kidney disease and developing new therapies. The purpose of this review is to provide an update on the promising therapies that are being developed and tested, based on knowledge of recent advances in molecular and cellular targets involved in cystogenesis.https://www.emjreviews.com/nephrology/article/new-therapies-targeting-cystogenesis-in-autosomal-polycystic-kidney-disease/Adult autosomal polycystic kidney disease (ADPKD)cystogenesisvasopressin 2 receptorssomatostatin analoguesmammalian target of rapamycin (mTOR) signalling. |
| spellingShingle | Maurizio Salvadori Aris Tsalouchos New Therapies Targeting Cystogenesis in Autosomal Polycystic Kidney Disease European Medical Journal Nephrology Adult autosomal polycystic kidney disease (ADPKD) cystogenesis vasopressin 2 receptors somatostatin analogues mammalian target of rapamycin (mTOR) signalling. |
| title | New Therapies Targeting Cystogenesis in Autosomal Polycystic Kidney Disease |
| title_full | New Therapies Targeting Cystogenesis in Autosomal Polycystic Kidney Disease |
| title_fullStr | New Therapies Targeting Cystogenesis in Autosomal Polycystic Kidney Disease |
| title_full_unstemmed | New Therapies Targeting Cystogenesis in Autosomal Polycystic Kidney Disease |
| title_short | New Therapies Targeting Cystogenesis in Autosomal Polycystic Kidney Disease |
| title_sort | new therapies targeting cystogenesis in autosomal polycystic kidney disease |
| topic | Adult autosomal polycystic kidney disease (ADPKD) cystogenesis vasopressin 2 receptors somatostatin analogues mammalian target of rapamycin (mTOR) signalling. |
| url | https://www.emjreviews.com/nephrology/article/new-therapies-targeting-cystogenesis-in-autosomal-polycystic-kidney-disease/ |
| work_keys_str_mv | AT mauriziosalvadori newtherapiestargetingcystogenesisinautosomalpolycystickidneydisease AT aristsalouchos newtherapiestargetingcystogenesisinautosomalpolycystickidneydisease |